Drugmakers see no marketing leverage from FDA biosim guidelines

Drugmakers had high hopes for the FDA's biosimilars labeling guidance; both reference-product drugmakers and copycats figured they might be able to use biosimilar labeling to their marketing advantage, depending on the language. But no dice, the FDA said late last week.

The agency took a stand for "generic-like" biosimilar labels, as Bernstein analyst Ronny Gal put it Friday to investors. The way regulators see it, data proving a drug's biosimilarity shouldn't make the cut; instead, labels should read like those of normal knockoffs. The FDA wants biosimilar labels to "contain the information needed by the physician to use the product--essentially the innovator's label," he wrote. And it wants no more than a "simple statement" about what biosimilarity means.

The results, if the guidance goes through? For one, reference-product makers won't be able to nitpick labeling data to argue against the adoption of biosimilars, the way AbbVie ($ABBV) envisioned when it last June released a citizen's petition supporting "a concise description of the pertinent data developed to support licensure."

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

On the other hand, biosimilar marketers won't be able to use their own labels to back their arguments against biosims from other developers. For "larger companies with strong marketing muscle" that "hoped to use their more robust clinical program as a commercial differentiator … this would be more challenging with this data not on the label," Gal noted.

The new guidance also weakens the "biosimilars are not generics" mantra that reference-product makers have repeated for some time now, to reassure investors that biosimilars wouldn't quickly tank their sales

But according to Gal, there are still multiple factors out there--such as interchangeability guidance, which is still yet to come--that could help biosimilars "to develop along either branded or generic lines." He thinks the "most likely trajectory" is "early development along branded lines with later transition to generic-like market structure." The content of the label is "only one, if meaningful, input into the mix."

- see the FDA's guidance (PDF)

Special Report: Top 20 generics companies by 2014 revenue

Read more on

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.